WO2009084036A3 - Composition for treatment of viral infections - Google Patents

Composition for treatment of viral infections Download PDF

Info

Publication number
WO2009084036A3
WO2009084036A3 PCT/IN2008/000843 IN2008000843W WO2009084036A3 WO 2009084036 A3 WO2009084036 A3 WO 2009084036A3 IN 2008000843 W IN2008000843 W IN 2008000843W WO 2009084036 A3 WO2009084036 A3 WO 2009084036A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
composition
viral infections
atazanavir
ritonavir
Prior art date
Application number
PCT/IN2008/000843
Other languages
French (fr)
Other versions
WO2009084036A2 (en
Inventor
Akhilesh Ashok Dixit
Indu Bhushan
Sanjay Deshraj Verma
Abhijit Mukund Deshmukh
Original Assignee
Matrix Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Limited filed Critical Matrix Laboratories Limited
Publication of WO2009084036A2 publication Critical patent/WO2009084036A2/en
Publication of WO2009084036A3 publication Critical patent/WO2009084036A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to stable solid dosage forms of ritonavir and atazanavir/tipranavir and processes for their preparation. In particular, the solid dosage form has improved stability, similar dissolution profile and being bioequivalent to the commercially available formulations of ritonavir and atazanavir.
PCT/IN2008/000843 2007-12-20 2008-12-18 Composition for treatment of viral infections WO2009084036A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3070/CHE/2007 2007-12-20
IN3070CH2007 2007-12-20

Publications (2)

Publication Number Publication Date
WO2009084036A2 WO2009084036A2 (en) 2009-07-09
WO2009084036A3 true WO2009084036A3 (en) 2009-12-30

Family

ID=40824850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000843 WO2009084036A2 (en) 2007-12-20 2008-12-18 Composition for treatment of viral infections

Country Status (1)

Country Link
WO (1) WO2009084036A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279728A1 (en) * 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
EP2621472A1 (en) * 2010-09-28 2013-08-07 Ratiopharm GmbH Dry processing of atazanavir
GB201118182D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
EP2958563A2 (en) * 2013-02-20 2015-12-30 AbbVie Inc. Tablet dosage form comprising ritonavir and lopinavir
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115690A1 (en) * 2000-10-31 2002-08-22 Shirlynn Chen Oral dosage self-emulsifying formulations of pyranone protease inhibitors
US20050143404A1 (en) * 2003-08-28 2005-06-30 Joerg Rosenberg Solid pharmaceutical dosage formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115690A1 (en) * 2000-10-31 2002-08-22 Shirlynn Chen Oral dosage self-emulsifying formulations of pyranone protease inhibitors
US20050143404A1 (en) * 2003-08-28 2005-06-30 Joerg Rosenberg Solid pharmaceutical dosage formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOEQUIVALENCE STUDY OF GENERIC GPO RITONAVIR VERSUS NORVIR, 28 November 2007 (2007-11-28), Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00477126/2007_11_28> [retrieved on 20090717] *
SCIENTIFIC DISCUSSION ON REYATAZ., 2005, pages 3 *

Also Published As

Publication number Publication date
WO2009084036A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
IL214942A (en) N,n-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments
WO2011014850A3 (en) Topical eutectic-based formulations
MY143795A (en) Tetrahydropyridoindole derivatives
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2010021607A3 (en) Pharmaceutical formulation
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2010084115A3 (en) Antiviral agents
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007075858A3 (en) Novel forms of tiotropium bromide and processes for preparation thereof
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
IL177658A0 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2009084036A3 (en) Composition for treatment of viral infections
WO2010049449A3 (en) Novel salts of sunitinib
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
WO2007083190A3 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
WO2006021401A3 (en) Bicylononene derivatives
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007082208A3 (en) Lanthionine-related compounds for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868926

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08868926

Country of ref document: EP

Kind code of ref document: A2